Evidence map›Paper›PMID 29156674›Full record

ArticleOncotarget2017

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.

Irene Brana, Nhu-An Pham, Lucia Kim, Shingo Sakashita, Ming Li, Christine Ng, Yuhui Wang, Peter Loparco, Rafael Sierra, Lisa Wang and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Irene BranaPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Nhu-An PhamPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lucia KimPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Shingo SakashitaPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Ming LiPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Christine NgPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Yuhui WangPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Peter LoparcoPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Rafael SierraPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lisa WangPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Blaise A ClarkeDepartment of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Benjamin G NeelPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lillian L SiuPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Ming-Sound TsaoPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
University Health Network · CAUniversity of Toronto · CAPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PTEN inactivation occurs commonly in human cancers and putatively activates the PI3K/AKT/ mTOR pathway. Activation of this pathway has been involved in resistance to chemotherapy or anti-EGFR/HER2 therapies. We evaluated the combination of PI3K-mTOR inhibitors with chemotherapy or the pan-HER inhibitor dacomitinib in PTEN-deficient patient-derived tumor xenografts (PDX). Three PDXs were selected for their lack of PTEN expression by immunohistochemistry: a triple-negative breast cancer (TNBC), a

Indexed as

chemotherapydacomitinibPI3KPTENxenograft

Identifiers

PMID29156674
PMCPMC5689564
OpenAlexW2724281455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.